What Megestoral treats: main uses and benefits

Megestoral may be an important therapeutic agent commonly used to help manage highly distressing consequences of chronic illness, primarily addressing severe appetite loss (anorexia) and progressive involuntary weight loss (cachexia). This medicine is considered relevant for patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) who are experiencing unexplained, significant weight loss.

The core indications for which this medication is relevant are supporting patients experiencing anorexia, cachexia, or unexplained, significant weight loss in the context of chronic, debilitating disease. In these contexts, the goal of treatment is supportive care.

“The primary benefit helps address symptoms related to loss of appetite, which helps to increase food intake.”

By supporting increased caloric intake, the medication assists with the management of the nutritional deficit, which may help support weight gain and contributes to overall improved comfort and assists with maintaining functional stability. This supports the patient during difficult episodes by easing distress.

---

Quick Fact: Support for Wasting Symptoms	Property	Description
Symptom Category	Symptoms that create noticeable physiological strain
Primary Indication	Anorexia and Wasting Syndrome (Cachexia)
Core Benefit	Supportive relief for symptoms related to nutritional deficit
Relevant Context	Chronic conditions marked by periods of heightened symptoms

Megestoral (megestrol acetate) is a medicine with specific regulatory restrictions defining its appropriate use. It is contraindicated and must not be used by individuals with a known hypersensitivity to megestrol acetate or any component in the formulation. Use is also strictly prohibited during known or suspected pregnancy due to the risk of fetal harm; females of reproductive potential must use effective contraception during therapy. Additionally, it is contraindicated as a diagnostic test for pregnancy.

Restrictions and Special Considerations

• Pediatric Use: Safety and effectiveness for use in pediatric patients have not been established.
• Older Adults (Geriatrics): Use requires caution, particularly due to the higher frequency of decreased heart, kidney, or liver function in this population, and the documented risk of thromboembolic events (blood clots).
• Condition-Specific Restrictions: The medicine should be used with caution in patients with a history of thromboembolic disease or diabetes mellitus, as it may worsen blood glucose control. It is also not intended for prophylactic use to prevent weight loss, nor should it be used in lieu of standard treatments like surgery or chemotherapy for cancer.

Interactions with other medicines and products

Official regulatory documents describe several interaction patterns for megestrol acetate, categorized primarily as pharmacokinetic interference and pharmacodynamic effects.

---

Pharmacokinetic Interactions

Interacting Medicine	Formal Regulatory Outcome
Indinavir (Antiviral)	Co-administration leads to a significant decrease in the systemic exposure (C max and AUC) of Indinavir.
Zidovudine, Rifabutin	Co-administration does not require a dosage adjustment, indicating a non-significant interaction.

Co-administration with Indinavir necessitates the regulatory consideration of administering a higher dose of Indinavir to compensate for the reduction in exposure. The original megestrol acetate oral suspension formulation exhibits a drug-food interaction; taking it with a high-fat meal significantly increases the total exposure of megestrol acetate itself.

---

Pharmacodynamic Effects and Restrictions

Megestrol acetate may cause impaired glucose tolerance or the exacerbation of pre-existing diabetes mellitus. This pharmacodynamic effect reduces the efficacy of co-administered Antidiabetic Agents, such as insulin, requiring monitoring. Use with Dofetilide is generally listed in official sources as a combination that is not recommended. The potential for exacerbated diabetes is a population-specific interaction note formally cited for patients with that condition.

Megestoral (megestrol acetate) functions as a synthetic steroid, primarily targeting and acting as an agonist for the nuclear progesterone receptor (PR). Upon binding to the cytosolic receptor, the ligand-receptor complex translocates into the cell nucleus, where it interacts with specific hormone response elements on the DNA. This interaction modulates gene transcription, leading to an alteration in the synthesis of specific proteins.

Furthermore, megestoral exhibits agonist activity toward the glucocorticoid receptor (GR), mediating systemic metabolic and endocrine effects through the resulting genomic and non-genomic pathways. This includes an effect on the hypothalamic-pituitary-adrenal (HPA) axis, with chronic administration leading to feedback inhibition and suppression of endogenous glucocorticoid production. At the systemic level, these receptor interactions result in the modulation of the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, decreasing the secretion of pituitary gonadotropins like luteinizing hormone (LH), thereby reducing peripheral hormone synthesis.

How Megestoral is Used

Megestrol acetate, the active ingredient in Megestoral, is administered exclusively via the oral route, utilizing either solid tablets or a liquid oral suspension. The specific recommended dosing regimen is determined by the indication and the concentration of the prescribed formulation.

Standard Adult Dosing Regimens

The frequency and dose vary based on the intended use:

Indication	Dosing Regimen	Frequency Pattern
Anorexia and Wasting Syndrome (Cachexia)	800 mg daily (conventional suspension) OR 625 mg daily (high-concentration suspension)	Once daily (QD)
Palliative Carcinoma	160 mg daily, often in divided doses (e.g., 40 mg up to four times daily)	Divided Doses

Administration and Duration Protocol

For the oral suspension, the container must be shaken well immediately before measurement and administration to ensure uniform distribution of the medicine. It is explicitly stated that the conventional 40 mg/mL and the high-concentration 125 mg/mL suspensions are not substitutable on a milligram-per-milligram basis.

Usage involves a commitment to a defined course duration for efficacy assessment. For cachexia, treatment should be evaluated after four continuous weeks. For palliative carcinoma, a minimum of two months of continuous therapy is typically required before assessing the efficacy of the regimen.

Population Considerations

Dosing for older adults should proceed cautiously, often initiating at the low end of the dosing range. The safety and effectiveness of megestrol acetate have not been established in the pediatric population.

Research Evidence / Overview of Studies for Megestoral

This section provides an overview of the official research evidence for Megestoral (Megestrol acetate), focusing on the types of clinical studies that have been conducted and the patterns observed. Research does not determine whether an individual will respond similarly.

---

Evidence for Use in AIDS-Related Wasting Syndrome

The research base for Megestoral's use in individuals presenting with involuntary weight loss and anorexia linked to AIDS or HIV infection includes short-term, randomized controlled trials (RCTs). These studies typically involved adults who had experienced significant, unexplained weight loss, and they often compared the medicine against a placebo over a defined time interval.

Researchers monitored changes in two main areas: overall body weight and subjective appetite levels. Findings from these studies described patterns where patients receiving the medicine reported increased appetite and data show patterns related to weight gain measurements when compared to those receiving the placebo. Research also explored the composition of this weight gain, with evidence suggesting that the increase in body mass may be mostly due to adipose (fat) tissue and fluid, rather than lean muscle mass.

---

Evidence for Use in Cancer-Related Cachexia Syndrome

Research has also evaluated Megestoral's use in patients with various advanced malignancies (cancers) presenting with anorexia and cachexia (wasting syndrome). This evidence base is built upon multiple RCTs and subsequent systematic reviews.

Studies examined patient-reported changes in appetite and objective assessments of overall body weight. Research describes patterns where increased appetite was frequently reported across many of these trials. However, data show patterns related to overall weight gain were mixed and varied across studies. Body composition measurements generally described that the change in body mass was primarily attributed to non-lean tissue.

---

What is Still Uncertain About Megestoral Research

Limited research has explored the pediatric population (children) presenting with cancer-related weight loss. Findings were mixed for these specific subgroups, and data for certain groups remain insufficient to draw general conclusions. The long-term effects are not fully established in the primary evidence base, as trials typically assessed outcomes over a period of 4 to 12 weeks.

Key Studies & References Review of megestrol acetate in pediatric cancer-related cachexia

Common questions about Megestoral (FAQ)

Q: How long does it typically take to start noticing the effects of Megestoral?

Studies examining the medicine's use for appetite stimulation and weight gain typically evaluated measurable changes over a period of 4 to 12 weeks. This pattern suggests that an assessment of the intended effects is typically done after a defined course of treatment, rather than immediately.

Q: Is Megestoral a type of hormone replacement therapy?

Megestrol acetate, the active ingredient, is classified as a synthetic progestin, meaning it is chemically similar to the hormone progesterone. Official documents categorize the medicine as an antineoplastic agent and progestogen, but do not classify it as Hormone Replacement Therapy (HRT).

Q: Are there any common supplements that should not be taken with Megestoral?

The official prescribing information details interactions with specific prescription medicines, such as certain antivirals and anti-diabetic agents. However, regulatory sources do not provide a specific list of common supplements to avoid. Official sources recommend informing a healthcare provider about all supplements being taken.

Q: Does Megestoral interact with common pain relievers like ibuprofen?

The official prescribing information focuses on several known drug interactions, but it does not list any interaction with common over-the-counter pain relievers such as ibuprofen. Official prescribing information is the primary source for details on specific drug combinations.

Q: Can Megestoral be used by both men and women?

Yes, according to official indications, Megestrol acetate is indicated for use in both men and women. It is prescribed for conditions such as the treatment of anorexia and cachexia (wasting syndrome) in certain patient populations.

Q: What should I do if I forget to take a dose of Megestoral?

Official guidance on a missed dose states that if it is almost time for the next scheduled dose, the missed dose should generally be skipped. Individuals should follow the specific instructions provided by their prescriber.

Q: Is it normal to feel tired after starting Megestoral?

Asthenia, which is a formal medical term for weakness or lack of energy, has been reported as a common adverse reaction in clinical trials. Furthermore, fatigue is noted as a symptom associated with the serious side effect of adrenal insufficiency.

Q: What is the risk of swelling or fluid retention with Megestoral?

Clinical research has described patterns where weight gain may be attributed to fluid accumulation in the body, in addition to fat tissue. Peripheral edema (swelling) has also been reported as an adverse event in regulatory documents.

Q: Does Megestoral affect birth control pills?

The medicine can cause suppression of the HPG axis, which is part of the hormone system. Regulatory documents recommend that females of reproductive potential use effective non-hormonal methods of contraception during therapy. Official documents do not explicitly detail the effect on the efficacy of oral birth control pills.

Q: Can Megestoral be taken with or without food?

Official information for the original liquid oral suspension notes a drug-food interaction where taking it with a high-fat meal may increase the medicine's absorption. For all formulations, patients are typically advised to follow the specific administration instructions provided by their prescriber.

Q: Are there common signs of an allergic reaction to Megestoral?

Known or suspected hypersensitivity (allergic reaction) to the drug or its components is a strict contraindication. Common adverse reactions reported include rash and pruritus (itching), which can be related to an allergic response. Official information advises prompt medical review in the event of a suspected serious adverse reaction.

Q: Can Megestoral interact with herbal supplements like St. John's Wort?

Regulatory labeling does not specifically mention interactions with herbal supplements such as St. John's Wort. Regulatory compliance suggests informing a healthcare professional about all herbal products and supplements being used.

Q: Does Megestoral require a special prescription or monitoring?

The medicine is a prescription-only item. Due to potential effects, official documents recommend that regular monitoring of blood glucose and renal function (kidney function) may be required during treatment.

Q: Is the evidence base for Megestoral mainly from small or large studies?

The evidence supporting the medicine's use includes high-quality research like randomized controlled trials (RCTs) and systematic reviews involving adult patients. While the types of studies are specified, the regulatory documents do not explicitly classify the research by the size of the patient groups.

Q: How does Megestoral's purpose relate to its chemical structure?

The medicine is a synthetic derivative of the natural steroid hormone progesterone. Its intended therapeutic purpose is directly linked to its chemical structure, which allows it to act as a progestin and influence hormone-responsive bodily systems.

Q: What are the documented safety classifications for Megestoral?

Official warnings classify megestrol acetate as a Category D drug during pregnancy, indicating positive evidence of risk to the human fetus. Its use is therefore strictly contraindicated (prohibited) in known or suspected pregnancy.

Megestrol Acetate must be stored under specific environmental conditions to maintain stability and effectiveness, according to official regulatory documentation.

Item	Official Storage Requirement
Temperature Range	Controlled room temperature: 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C (59 F and 86 F).
Protection	Store away from excess heat and moisture; the medicine should not be stored in the bathroom.
Packaging	Must be kept in the original container and kept tightly closed.
Child Safety	The product must be stored out of the reach of children.

For disposal of unused or expired medicine, regulatory guidance dictates that the product should not be flushed down the toilet. Instead, it must be mixed with an unappealing substance, such as dirt or used coffee grounds, and placed in a sealed bag or container before being discarded in the household trash.